The United States remains a key contributor to the growth of the Antispasmodics Drugs Market, driven by the rising prevalence of gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and functional digestive conditions. Strong healthcare infrastructure, high healthcare spending, and widespread access to advanced treatment options continue to...